Cargando…
Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance
AIM: Lusutrombopag is approved for the treatment of thrombocytopenia in chronic liver disease patients undergoing invasive procedures. This real‐world surveillance assesses the safety and effectiveness of lusutrombopag in Japan. METHODS: This ongoing, multicenter, prospective, real‐world surveillanc...
Autores principales: | Sasaki, Ritsue, Shiino, Chikako, Imawari, Michio, Bentley, Roy, Cai, Bin, Yoshida, Manami, Afdhal, Nezam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899664/ https://www.ncbi.nlm.nih.gov/pubmed/31228221 http://dx.doi.org/10.1111/hepr.13392 |
Ejemplares similares
-
Bleeding events in lusutrombopag‐treated thrombocytopenic patients
por: Giannini, Edoardo Giovanni, et al.
Publicado: (2021) -
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)
por: Peck‐Radosavljevic, Markus, et al.
Publicado: (2019) -
Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag
por: Brown, Robert S., et al.
Publicado: (2021) -
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020) -
Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance
por: Flamm, Steven L., et al.
Publicado: (2022)